Thioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxide

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 8, 2014, Pages 4765-4773

  Tan, Yingxia ^a   Bi, Laixi ^a   Zhang, Peili ^a   Wang, Fule ^a   Lin, Feiyan ^a   Ni, Wuhua ^a   Wu, Jianbo ^a   Jiang, Lei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Apoptosis; Arsenic trioxide; PX 12

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; DISULFIDE; IMIDAZOLE DERIVATIVE; IV 2 COMPOUND; ORGANOARSENIC DERIVATIVE; OXIDE; THIOREDOXIN; TXN PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL SURVIVAL; DRUG EFFECTS; FLOW CYTOMETRY; HL 60 CELL LINE; HUMAN; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DISULFIDES; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOID, ACUTE; OXIDES; THIOREDOXINS;

EID: 84907919427     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Pollyea DA, Kohrt HE and Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol 2011; 152: 524-542.
2. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD and European L. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
3. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY and Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052-1061.
4. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP and Warrell RP Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-1348.
5. Slack JL, Waxman S, Tricot G, Tallman MS and Bloomfield CD. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. Oncologist 2002; 7 Suppl 1: 1-13.
6. Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ and Chen Z. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2009; 106: 3342-3347.
7. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z and Wang ZY. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
8. Li Y, Zhu X, Gu J, Dong D, Yao J, Lin C, Huang K and Fei J. Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer Sci 2010; 101: 948-954.
9. Gao SM, Chen C, Wu J, Tan Y, Yu K, Xing CY, Ye A, Yin L and Jiang L. Synergistic apoptosis induction in leukemic cells by miR-15a/16-1 and arsenic trioxide. Biochem Biophys Res Commun 2010; 403: 203-208.
10. Tonissen KF and Di Trapani G. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res 2009; 53: 87-103.
11. Yoshihara E, Masaki S, Matsuo Y, Chen Z, Tian H and Yodoi J. Thioredoxin/Txnip: Redoxisome, as a Redox Switch for the Pathogenesis of Diseases. Front Immunol 2014; 4: 514.
12. Wondrak GT. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal 2009; 11: 3013-3069.
13. Jordan BF, Runquist M, Raghunand N, Gillies RJ, Tate WR, Powis G and Baker AF. The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging. Clin Cancer Res 2005; 11: 529-536.
14. Baker AF, Dragovich T, Tate WR, Ramanathan RK, Roe D, Hsu CH, Kirkpatrick DL and Powis G. The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. J Lab Clin Med 2006; 147: 83-90.
15. Kirkpatrick L, Dragovich T, Ramanathan R, Sharlow E, Chow S, Williams D, Himler R, Baker A and Egorin M. Results from Phase I study of PX-12, a thioredoxin inhibitor in patients with advanced solid malignancies. J Clin Oncol 2004; 22: 3089.
16. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL and Powis G. The Thioredoxin Redox Inhibitors 1-Methylpropyl 2-Imidazolyl Disulfide and Pleurotin Inhibit Hypoxia-induced Factor 1α and Vascular Endothelial Growth Factor Formation 1. Mol Cancer Ther 2003; 2: 235-243.
17. Mukherjee A and Martin SG. The thioredoxin system: a key target in tumour and endothelial cells. Br J Radiol 2008; 81: S57-68.
18. Gao SM, Yang J, Chen C, Zhang S, Xing CY, Li H, Wu J and Jiang L. miR-15a/16-1 enhances retinoic acid-mediated differentiation of leukemic cells and is up-regulated by retinoic acid. Leuk Lymphoma 2011; 52: 2365-2371.
19. Jiang L, Chen Y, Chan CY, Wang X, Lin L, He ML, Lin MC, Yew DT, Sung JJ, Li JC and Kung HF. Down-regulation of stathmin is required for TGF-beta inducible early gene 1 induced growth inhibition of pancreatic cancer cells. Cancer Lett 2009; 274: 101-108.
20. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG and Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102-2111.
21. Thein MS, Ershler WB, Jemal A, Yates JW, Baer MR. Outcome of older patients with acute myeloid leukemia. Cancer 2013; 119: 2720-2727.
22. Igney FH and Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002; 2: 277-288.
23. Smits EL, Berneman ZN and Van Tendeloo VF. Immunotherapy of acute myeloid leukemia: current approaches. Oncologist 2009; 14: 240-252.
24. Szer J. The prevalent predicament of relapsed acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2012; 2012: 43-48.
25. Kupsa T, Horacek JM and Jebavy L. The role of cytokines in acute myeloid leukemia: a systematic review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012; 156: 291-301.
26. Powis G and Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Biophys Biomol Struct 2001; 30: 421-455.
27. Raffel J, Bhattacharyya AK, Gallegos A, Cui H, Einspahr JG, Alberts DS and Powis G. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 2003; 142: 46-51.
28. You BR, Shin HR and Park WH. PX-12 inhibits the growth of A549 lung cancer cells via G2/M phase arrest and ROS-dependent apoptosis. Int J Oncol 2014; 44: 301-308.
29. Ramanathan RK, Abbruzzese J, Dragovich T, Kirkpatrick L, Guillen JM, Baker AF, Pestano LA, Green S and Von Hoff DD. A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother Pharmacol 2011; 67: 503-509.
30. Shin HR, You BR and Park WH. PX-12-induced HeLa cell death is associated with oxidative stress and GSH depletion. Oncol Lett 2013; 6: 1804-1810.
31. Ramanathan RK, Kirkpatrick DL, Belani CP, Friedland D, Green SB, Chow HS, Cordova CA, Stratton SP, Sharlow ER and Baker A. A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin Cancer Res 2007; 13: 2109-2114.
32. Lin TH, Lu FJ, Yin YF and Tseng TH. Enhancement of esculetin on arsenic trioxide-provoked apoptosis in human leukemia U937 cells. Chem Biol Interact 2009; 180: 61-68.
33. Cohen G. Caspases: the executioners of apoptosis. Biochem J 1997; 326: 1-16.
34. Bachleitner-Hofmann T, Kees M and Gisslinger H. Arsenic trioxide: acute promyelocytic leukemia and beyond. Leuk Lymphoma 2002; 43: 1535-1540.
35. Berenson JR and Yeh HS. Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy. Clin Lymphoma Myeloma 2006; 7: 192-198.
36. Nakagawa Y, Akao Y, Morikawa H, Hirata I, Katsu K, Naoe T, Ohishi N and Yagi K. Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci 2002; 70: 2253-2269.
37. Oketani M, Kohara K, Tuvdendorj D, Ishitsuka K, Komorizono Y, Ishibashi K and Arima T. Inhibition by arsenic trioxide of human hepatoma cell growth. Cancer Lett 2002; 183: 147-153.
38. Shao QS, Ye ZY, Ling ZQ and Ke JJ. Cell cycle arrest and apoptotic cell death in cultured human gastric carcinoma cells mediated by arsenic trioxide. World J Gastroenterol 2005; 11: 3451-6.
39. Trachootham D, Alexandre J and Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009; 8: 579-591.
40. Miller WH, Schipper HM, Lee JS, Singer J and Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62: 3893-3903.
41. Wang DH, Wei HL, Zhao HS, Hao CY, Min ZH and Liu JM. Arsenic trioxide overcomes apoptosis inhibition in K562/ADM cells by regulating vital components in apoptotic pathway. Pharmacol Res 2005; 52: 376-385.
42. Wei H, Su H, Bai D, Zhao H, Ge J, Wang B, Yao X and Ma L. Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene. Chin Med J (Engl) 2003; 116: 1644-1648.
43. Tian C, Gao P, Zheng Y, Yue W, Wang X, Jin H and Chen Q. Redox status of thioredoxin-1 (TRX1) determines the sensitivity of human liver carcinoma cells (HepG2) to arsenic trioxide-induced cell death. Cell Res 2008; 18: 458-471.